Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Organisation › Details

Oculis S.A.

Oculis is a global biopharmaceutical company (NASDAQ: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. Oculis’ shares and warrants will trade on the Nasdaq Stock Market under the ticker symbols “OCS” and “OCSAW”, respectively. *


Period Start 2019-01-04 existent
  Group Oculis (Group)
Products Industry solubilizing nanoparticle (SNP) drug delivery platform (Oculis)
  Industry 2 OC-118 (Oculis)
Persons Person Sherif, Riad (Oculis 201801– CEO before Novartis Area President EMEA at Alcon)
  Person 2 Jóhannesson, Páll Ragnar (Oculis 201801– CFO Oculis SA + Managing Director Oculis ehf before CEO Oculis)
  Street EPFL Innovation Park, Building C
EPFL Innovation Park, Building C
  City 1015 Lausanne VD
  Tel +41-21-711-3970
    Address record changed: 2023-03-09
Basic data Employees n. a.
    * Document for »About Section«: Oculis Holding AG. (3/3/23). "Press Release: Oculis Announces US Public Listing on NASDAQ". Lausanne & Zug.
Record changed: 2023-07-10


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for Oculis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px

» top